Top

Published in:

01-06-2006 | Editorial

Mucositis guidelines: what have they achieved, and where to from here?

Author: Dorothy M. K. Keefe

Published in: Supportive Care in Cancer | Issue 6/2006

Excerpt

Mucositis remains one of the most troublesome side effects of anti-cancer treatment with chemotherapy, radiotherapy, or a combination of both. It is also one of the ‘Cinderella’ areas in oncology: curing mucositis is not as exciting a prospect as curing cancer, but it would improve the quality of life of thousands of cancer sufferers annually. Again, like Cinderella, it is often ignored by the oncology community. What we cannot help we would rather not think about. …

Rubenstein EB et al (2004) Clinical practice guidelines for the prevention and treatment of cancer therapy-induced oral and gastrointestinal mucositis. Cancer 100(9 Suppl):2026–2046CrossRefPubMed

Sonis ST et al (2004) Perspectives on cancer therapy-induced mucosal injury: pathogenesis, measurement, epidemiology, and consequences for patients. Cancer 100(9 Suppl):1995–2025CrossRefPubMed

MASCC/ISOO, T.M.s.g.o. (2005) Summary of evidence-based clinical practice guidelines for care of patients with oral and gastrointestinal mucositis (2005 update). http://www.mascc.org

Keefe DM, Peterson DE, Schubert MM (2006) Developing evidence-based guidelines for management of alimentary mucositis: process and pitfalls. Support Cancer Therapy (in press)

Peterson D, Keefe D, Hutchins R, Schubert M (2005) Alimentary tract mucositis in cancer patients: impact of terminology and assessment on research and clinical practice. Support Care Cancer (in press)

Jones J, Avritsher E, Cooksley C, Michelet M, Nebiyou Bekele B, Elting L (2005) Epidemiology of treatment associated mucosal injury after treatment with newer regimens for lymphoma, breast, lung, or colorectal cancer. Support Care Cancer (in press)

Anthony L, Bowen J, Garden A, Hewson I, Sonis S (2005) New thoughts on the pathobiology of regimen-related mucosal injury. Support Care Cancer (in press)

von Bultzingslowen I, Brennan M, Spijkervet F, Logan R, Stringer A, Raber J, Keefe DM (2005) Growth factors and cytokines in the prevention and treatment of oral and gastrointestinal mucositis. Support Care Cancer (in press)

Altman A, Barasch A, Damato K, Elad S, Epstein J (2005) Antimicrobials, mucosal coating agents, anesthetics, analgesics and nutritional supplements in alimentary mucositis. Support Care Cancer (in press)

10.

Migliorati C, Oberle-Edwards L, Schubert M (2005) The role of alternative and natural agents, ice, and laser in the management of alimentary tract mucositis. Support Care Cancer (in press)

11.

McGuire D, Johnson J, Wienandts P, Correa E (2005) The role of basic oral care and good clinical practice principles in the management of oral mucositis. Support Care Cancer (in press)

12.

McGuire DB, Johnson J, Migliorati C (2005) Promulgation of guidelines for mucositis management: educating health care professionals and patients. Support Care Cancer (in press)

13.

Lalla R, Schubert M, Bensadoun R-J, Keefe D (2005) Anti-inflammatory agents in the management of alimentary mucositis. Support Care Cancer (in press)

14.

Bensadoun R-J, Schubert M, Lalla R, Keefe D (2005) Amifostine in the management of radiation-induced and chemotherapy-induced alimentary mucositis. Support Care Cancer (in press)

15.

Keefe D, Lees J, Horvath N (2005) Palifermin for oral mucositis: the Royal Adelaide Hospital experience. Support Care Cancer (in press)

16.

Brennan M, von Bultzingslowen I, Schubert M, Keefe D (2005) Alimentary mucositis: putting the guidelines into practice. Support Care Cancer (in press)

17.

Spielberger R et al (2004) Palifermin for oral mucositis after intensive therapy for hematologic cancers (see comment). N Engl J Med 351(25):2590–2598CrossRefPubMed

18.

Min D et al (2002) Protection from thymic epithelial cell injury by keratinocyte growth factor: a new approach to improve thymic and peripheral T-cell reconstitution after bone marrow transplantation. Blood 99(12):4592–4600CrossRefPubMed

19.

Farrell CL et al (2002) The effects of keratinocyte growth factor in preclinical models of mucositis. Cell Prolif 35(Suppl 1):78–85CrossRefPubMed

20.

Gibson R, Keefe DM (2006) Cancer chemotherapy-induced diarrhoea and constipation: mechanisms of damage, possible prevention strategies and treatment of the clinical problem. Support Care Cancer (in press)

21.

The Antiemetic Study Group of MASCC (2005) The 2004 Perugia international antiemetic conference. Support Care Cancer 13(2):77–133CrossRef

Title: Mucositis guidelines: what have they achieved, and where to from here?
Author: Dorothy M. K. Keefe
Publication date: 01-06-2006
Publisher: Springer-Verlag
Published in: Supportive Care in Cancer / Issue 6/2006
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI: https://doi.org/10.1007/s00520-006-0056-3

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 6/2006

Epidemiology of treatment-associated mucosal injury after treatment with newer regimens for lymphoma, breast, lung, or colorectal cancer

Forthcoming Meetings

Abstracts

Amifostine in the management of radiation-induced and chemo-induced mucositis

Alimentary mucositis: putting the guidelines into practice

Antimicrobials, mucosal coating agents, anesthetics, analgesics, and nutritional supplements for alimentary tract mucositis

Keynote webinar | Spotlight on antibody–drug conjugates in cancer